Thursday, November 11, 2021
Axcella Therapeutics (AXLA)
3Q21 Marked By Clinical Progress
Axcella is a clinical-stage biotechnology company pioneering a new approach to treat complex diseases using endogenous metabolic modulator (EMM) compositions. The company’s product candidates are comprised of EMMs and derivatives that are engineered in distinct combinations and ratios to reset multiple biological pathways, improve cellular energetics, and restore homeostasis. Axcella’s pipeline includes lead therapeutic candidates in Phase 2 development for the reduction in risk of overt hepatic encephalopathy (OHE) recurrence, the treatment of Long COVID, and the treatment of non-alcoholic steatohepatitis (NASH). The company’s unique model allows for the evaluation of its EMM compositions through non-IND clinical studies or IND clinical trials. For more information, please visit www.axcellatx.com.
Robert LeBoyer, Senior Research Analyst, Noble Capital Markets, Inc.
Refer to the full report for the price target, fundamental analysis, and rating.
3Q21 Reported A Smaller Loss Than Expected. During the quarter, Axcella made significant progress enrolling its two clinical trials, had scientific studies accepted for presentation, and announced a new indication for AXA1125. The company’s loss for the quarter was $15.6 million or $(0.41) per share, compared with our estimated loss of $16.1 million or $(0.43) per share. The quarter ended with $66.1 million in cash.
A New Trail For AXA1125 In Long COVID. Recent studies have indicated that COVID-19 infection can have damaging effects on mitochondria, changing energy production in the cells, and causing long-term fatigue. The AXA1125 mechanism of action impacts mitochondria and may be able to restore normal activity. A Phase 2a study in Long COVID patients is planned, with a target enrollment is about 40 …
This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).
*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision.
